Publication Listing for the MeSH term drug therapy. Found 338 abstracts

no pagination

Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017 Jan;18(1):31-41.   PMCID: PMC5476941

Mirhadi AJ, Zhang Q, Hanks GE, Lepor H, Grignon DJ, Peters CA, Rosenthal SA, Zeitzer K, Radwan JS, Lawton C, Parliament MB, Reznik RS, Sandler HM. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Mar;97(3):511-5.   PMCID: PMC5485922

Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr;35(10):1112-8.   PMCID: PMC5559878

Pollack A, Kwon D, Walker G, Khor LY, Horwitz EM, Buyyounouski MK, Stoyanova R. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer. Journal of the National Cancer Institute. 2017 Feb;109(2):1-8.

Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schonland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017 Aug 03;130(5):597-605.

Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017 Jul;58:70-6.

Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017 Apr;3(4):483-91.   PMCID: PMC5470422

Weng YL, An R, Cassin J, Joseph J, Mi R, Wang C, Zhong C, Jin SG, Pfeifer GP, Bellacosa A, Dong X, Hoke A, He Z, Song H, Ming GL. An Intrinsic Epigenetic Barrier for Functional Axon Regeneration. Neuron. 2017 Apr 19;94(2):337-346e6.

Borghaei H, Brahmer J. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer [comment]. The New England journal of medicine. 2016 Feb 04;374(5):493-4.   PMCID: NA

Burtness B, Powell M, Catalano P, Berlin J, Liles DK, Chapman AE, Mitchell E, Benson AB. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. Am J Clin Oncol. 2016 Aug;39(4):340-5.   PMCID: PMC4177955

Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. The New England journal of medicine. 2016 Feb 25;374(8):738-48.   PMCID: PMC5081077

Chwistek M, Ewerth N. Opioids and Chronic Pain in Cancer Survivors: Evolving Practice for Palliative Care Clinics. J Palliat Med. 2016 Mar;19(3):254.

Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Muschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. 2016 Apr 28;127(17):2131-43.   PMCID: PMC4850868

Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, van Rhijn BW, Fransen van de Putte EE, Zareba P, Koskinen I, Kassouf W, Traboulsi SL, Kukreja JE, Bostrom PJ, Shayegan B, Pinthus JH. Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. J Urol. 2016 Dec;196(6):1627-33.

Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, van Rhijn BW, Fransen van de Putte EE, Zareba P, Koskinen I, Kassouf W, Traboulsi SL, Kukreja JE, Bostrom PJ, Shayegan B, Pinthus JH. Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. J Urol. 2016 Dec;196(6):1627-33.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016 Mar;14(3):255-64.

Gupta S, Wang L, Kruger WD. Betaine supplementation is less effective than methionine restriction in correcting phenotypes of CBS deficient mice. J Inherit Metab Dis. 2016 Aug;39(1):39-46.   PMCID: 4784539

Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 Mar 08;387(10032):2008-16.   PMCID: 4878938

Patel D, Antwi J, Koneru PC, Serrao E, Forli S, Kessl JJ, Feng L, Deng N, Levy RM, Fuchs JR, Olson AJ, Engelman AN, Bauman JD, Kvaratskhelia M, Arnold E. A New Class of Allosteric HIV-1 Integrase Inhibitors Identified by Crystallographic Fragment Screening of the Catalytic Core Domain. The Journal of biological chemistry. 2016 Nov 04;291(45):23569-77.   PMCID: PMC5095411

Seeger C, Mason WS. HBV replication, pathobiology and therapy: Unanswered questions. J Hepatol. 2016 Apr;64(1 Suppl):S1-3.

The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

drug therapy therapeutic use Middle Aged Male Female Disease-Free Survival administration & dosage Antineoplastic Agents Aged adverse effects analogs & derivatives pathology Survival Rate drug effects Monoclonal Antibodies methods chemistry Lung Neoplasms Adenocarcinoma metabolism mortality Non-Small-Cell Lung Carcinoma analysis Taxoids Antineoplastic Combined Chemotherapy Protocols Follow-Up Studies blood antagonists & inhibitors chemically induced physiology Squamous Cell Carcinoma Drug Administration Schedule Monoclonal Antibodies-Humanized pharmacology Prostatic Neoplasms Kaplan-Meier Estimate 80 and over Aged Ovarian Neoplasms Treatment Outcome Oral Administration thromboembolism Hormonal Antineoplastic Agents genetics neoadjuvant therapy cystectomy Inbred C57BL Mice urinary bladder neoplasms Adult Prostate-Specific Antigen Diarrhea Androgen Antagonists Tumor Biomarkers Cetuximab Response Evaluation Criteria in Solid Tumors Combined Modality Therapy virology Mice radiotherapy Immune-related adverse events Tet1 bcl-2-Associated X Protein Bone Density Neoplastic Stem Cells Proto-Oncogene Proteins c-abl Immunosuppressive Agents Experimental Leukemia Cyclooxygenase 2 Ki-67 Antigen Melanoma Molecular Docking Simulation Intention to Treat Analysis Fatigue Chemoradiotherapy epidemiology Tdg Hypotension CA-19-9 Antigen allosteric inhibitor Camptothecin Thiophenes Methionine Betaine Cisplatin Area Under Curve Dietary Supplements Phenylurea Compounds fragment screening Molecular Models Proto-Oncogene Proteins p21(ras) Fallopian Tube Neoplasms Nivolumab HIV-1 Dose Fractionation Substance Abuse Detection Carboxylic Acids Catalytic Domain CTLA-4 Antigen Weight Loss integrase X-Ray Crystallography drug screening Peripheral Nerve Injuries Oxidative Stress Proportional Hazards Models Pancreatic Neoplasms Animal Disease Models Diet Pain Pyridazines Proto-Oncogene Proteins c-bcl-2 Pyrroles Palliative Care Paclitaxel therapy Prospective Studies Enoxaparin etiology Imidazoles Amyloidosis cytology Weight Gain adverse Spinal Ganglia Bevacizumab Allosteric Regulation Double-Blind Method Hepatitis B virus HEK293 Cells Cell Division statistics & numerical data Thyroiditis Tet3 Practice Guidelines as Topic Retrospective Studies effects Kidney Neoplasms Prognosis Thromboembolism abl Genes Neoplasm Drug Resistance Chronic Hepatitis B Retreatment human immunodeficiency virus (HIV) Protein Kinase Inhibitors Glycine Tumor Suppressor Genes Genomic Instability Drug Discovery Platinum Compounds axon regeneration